LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/13/2018 |
| Start Date: | November 2013 |
| End Date: | September 2021 |
| Contact: | Elise Tjaden, MPH |
| Email: | Elise.Tjaden@atriumhealth.org |
| Phone: | 980-442-9437 |
LCI-HEM-SPEC-001: Tissue Collection for Familial Acute Myelogenous Leukemia Genetic Analysis
The purpose of this study is to obtain high quality specimens for molecular studies for the
identification and characterization of genetic mutations involved in the pathogenesis of
familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic
clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for
molecular analyses. Some specimens sent to Washington University may also be used for quality
control analyses.
identification and characterization of genetic mutations involved in the pathogenesis of
familial myeloid malignancies. Specimens obtained will be de-identified, linked to basic
clinical data, and sent to Washington University (Division of Oncology, St. Louis, MO) for
molecular analyses. Some specimens sent to Washington University may also be used for quality
control analyses.
This is a specimen collection study for patients receiving standard of care treatment for
AML. Specimens collected will be 1) bone marrow biopsy and aspiration, 2) peripheral blood,
3) skin punch biopsy, and 4) oral rinse. Collection of these specimens will be at timepoints
determined by the patient's standard of care and their physician Investigator.
AML. Specimens collected will be 1) bone marrow biopsy and aspiration, 2) peripheral blood,
3) skin punch biopsy, and 4) oral rinse. Collection of these specimens will be at timepoints
determined by the patient's standard of care and their physician Investigator.
Inclusion Criteria
- Patients must have a diagnosis of acute myelogenous leukemia.
- Family members of patients with acute myelogenous leukemia may be enrolled.
- Informed consent must be provided by the patient or his/her legal guardian in accord
with the practices of Levine Cancer Institute and Carolinas Healthcare System.
Exclusion Criteria
- Known infection with Hepatitis B or C, HTLV, or HIV.
We found this trial at
1
site
Charlotte, North Carolina 28211
Principal Investigator: Belinda Avalos, M.D.
Click here to add this to my saved trials
